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Thegenerationofinducedpluripotentstemcells(iPSCs)fromsomaticcellshasenabledthepossibilityofprovidingunprecedented
access to patient-speciﬁc iPSC cells for drug screening, disease modeling, and cell therapy applications. However, a major obstacle
to the use of iPSC for therapeutic applications is the potential of genomic modiﬁcations caused by insertion of viral transgenes
in the cellular genome. A second concern is that reprogramming often requires the use of animal feeder layers and reagents that
contain animal origin products, which hinder the generation of clinical-grade iPSCs. Here, we report the generation of iPSCs
by an RNA Sendai virus vector that does not integrate into the cells genome, providing transgene-free iPSC line. In addition,
reprogramming can be performed in feeder-free condition with StemPro hESC SFM medium and in xeno-free (XF) conditions.
Generation of an integrant-free iPSCs generated in xeno-free media should facilitate the safe downstream applications of iPSC-
based cell therapies.
1.Introduction
Takahashi and Yamanaka ﬁrst demonstrated that induced
pluripotentstemcells(iPSCs)canbegeneratedfromsomatic
cells by transducing four transcription factors using retro-
viral vectors [1, 2]. This breakthrough in creating induced
pluripotentstemcellsopenedthedoorforpersonalizedmed-
icine using patient-derived iPSCs [3–6]. The major limita-
tion for potential clinical application is the integration of
viral transgenes into the host genome that can result in
multipleinsertionsandriskoftumorigenicity[7,8].Another
major disadvantage of reprogramming cells with integrating
vectors is that silencing and activation of transgenes are
unpredictable, which may aﬀect terminal diﬀerentiation po-
tential and increase the risk of using iPSC-derived cells. Mul-
tiple methods have been developed to address these issues,
including reprogramming with episomal vectors, mRNAs,
miRNAs, protein transduction, or treatment with chemical
compounds [9]. The majority of these methods has one or
more limitations, such as low reprogramming eﬃciency or
requiringmultipleroundsoftransfections,oriseﬀectiveonly
with speciﬁc cell types, such as skin ﬁbroblasts. We have pre-
viously shown that sustained expression of reprogramming
factorsisrequiredforatleast10–20days[10],andoftenthese
reprogramming methods fail to sustain expression and are
diﬃcult to repeat. Further, due to poor eﬃciency of existing
methods, reprogramming often has been performed in the
presence of animal feeders (inactivated mouse embryonic
ﬁbroblasts) to maximize colony formation [11] along with
the use of serum and xeno-containing products, which are
not ideal for clinical applications [11, 12].
Here, we investigate the use of Sendai virus vector to
generate transgene-free iPSCs in diﬀerent conditions. Sendai
virus vector is a negative-strand RNA virus that belongs
to the paramyxoviridae family [13–15]. Unlike other RNA
viruses, it replicates in the cytoplasm of infected cells and2 Stem Cells International
does not go through a DNA phase that can integrate into the
host genome [13]. In addition, Sendai virus vector can infect
a broad host range and is nonpathogenic to humans. Sendai
virus vector has been considered for clinical studies of gene
therapy for cystic ﬁbrosis [16, 17] and vaccine delivery [18].
RecentpapersalsodemonstratedthatSendaivirusvectorcan
reprogram somatic cells with higher eﬃciency than other
reprogramming methods [19]. Thus, the nature of Sendai
virus vector makes it an ideal tool for cell reprogramming
and stem cell research.
The current methods of reprogramming often require
the use of inactivated feeders and animal-derived products
during several steps to maximize reprogramming eﬃciency.
However, exposure of human cells to animal origin products
may increase the risk of nonhuman pathogen transmission
and immune rejection [20], hence limiting their use in clin-
ical settings. Given the reported high eﬃciency of Sendai
virus vector in generating pluripotent cells, we investigated
the generation of transgene-free iPSCs with Sendai virus
vector in feeder-free conditions using StemPro hESC SFM
medium and in xeno-free conditions. Several reports have
demonstratedthegenerationofiPSCsinanimalproduct-free
culture media but their performance tends to be lower than
knockout serum (KO-SR) based media [21]. Here, we report
ar o b u s ta n da ne ﬃcient system to generate transgene-free
iPSCs in diﬀerent conditions, and its ease of use can be
applied to a wide range of diﬀerent cell types. Generation of
transgene-free iPSCs under these conditions will be impor-
tant to facilitate the safe clinical translation of iPSC-based
therapies.
2.MaterialsandMethods
2.1. Cell Culture. Human neonatal ﬁbroblasts (ATCC Cat.
no. CRL-2252) were maintained in ﬁbroblast growth media
consisting of DMEM + GlutaMAX (Cat. no. 10569-010),
supplemented with 10% ES cell-qualiﬁed fetal bovine serum
(Cat. no. 16141-079), and 1% nonessential amino acids
(Cat. no. 11140-050). Feeder-free iPSC cultures were main-
tained on hESC-qualiﬁed GelTrex (Cat. no. A10480-02) with
chemically deﬁned StemPro hESC SFM (Cat. no. A1000701)
supplemented with 100μM 2-mercaptoethanol (Cat. no.
21985-023) and 10ng/mL recombinant human basic FGF
(Cat. no. PHG0264). For xeno-free culture, human neonatal
ﬁbroblasts were maintained in StemPro MSC SFM Xeno-
Free medium (Cat. no. A10675-01). Xeno-free iPSC cul-
tures were maintained on KnockOut-DMEM/F-12 (Cat. no.
12660012) supplemented with 15% KnockOut-SR Xeno-
Free CTS (Cat. no. A1099202), 1X KnockOut SR Xeno-
Free Growth Factor Cocktail, 2mM GlutaMAX (Cat. no.
35050-061), 1% nonessential amino acids, 100μM 2-mer-
captoethanol, and 20ng/mL of bFGF. For feeder condition,
human iPS cells were maintained on irradiated mouse
embryonic ﬁbroblasts (Cat. no. S1520-100) in DMEM/F-
12 + GlutaMAX (Cat. no. 10565-018) supplemented with
20% KnockOut SR (Cat. no. 10828-028), 1% nonessential
amino acids, 100μM 2-mercaptoethanol, and 4ng/mL of
bFGF.iPSCswerepassagedmanuallyusinga26-gaugeneedle
or StemPro EZPassage Disposable Stem Cell Passaging Tool
(Cat.no.23181-010).AllreagentsarefromLifeTechnologies.
Colonies were passaged every 3-4 days at a splitting ratio of
1:3. The Gibco Episomal hiPSC line was purchased from
Life Technologies (Cat. no. A13777) and maintained on
irradiated mouse embryonic ﬁbroblasts in DMEM/F-12 +
GlutaMAX supplemented with 20% KnockOut SR, 1%
nonessential amino acids, 100μM 2-mercaptoethanol, and
4ng/mL bFGF.
2.2. Generation of iPSCs in Feeder-Free and Xeno-Free Condi-
tions. For the generation of iPSCs in feeder-free condition,
approximately 100,000 human neonatal ﬁbroblasts were
seeded per well in a 6-well plate and incubated at 37◦C
and 5% CO2. Two days later, cells were transduced with the
CytoTune iPS Reprogramming Kit containing Sendai virus
vectors using the F gene-defective vector as described in
[19, 22] (Life Technologies Cat. no. A1378001) in ﬁbroblast
growth medium at an MOI of 3, as described in the
manufacturer’s protocols. One day after transduction, the
medium was replaced with fresh ﬁbroblast growth medium
andthecellswereculturedinﬁbroblastgrowthmediafor6-7
days. On day eight after transduction, cells were transferred
to 10cm Geltrex-coated tissue culture dishes at 5 × 105 cells
per dish. After culturing overnight in ﬁbroblast growth me-
dia, the medium was replaced daily with StemPro hESC SFM
medium. The iPSC colonies were picked for expansion and
characterization from days 17–21 of reprogramming.
For the generation of iPSCs in xeno-free condition, ap-
proximately500,000 humanneonatalﬁbroblastswereseeded
inStemProMSCSFMXeno-Freemediumperwellina6-well
plate and incubated at 37◦C and 5% CO2. The next day, cells
were transduced with the CytoTune iPS Reprogramming Kit
in StemPro MSC SFM Xeno-free medium at an MOI of
3. One day after transduction, the medium was replaced
with fresh StemPro MSC SFM Xeno-Free medium and cells
were cultured for 6-7 days. On day eight after transduction,
cells were transferred to 10cm tissue culture dishes plated
with inactivated human feeders (NuFF, GlobalStem Cat. no.
GSC-3001G) at a density of 2×105 cells per dish. After
culturing overnight, the medium was replaced daily with
xeno-freeiPSCmedium.Thexeno-freemediumiscomposed
of KnockOut D-MEM CTS containing 15% KnockOut
SR Xeno-Free CTS, 2mM GlutaMAX, KnockOut SR GF
Cocktail CTS (used at 1:50), and 8ng/mL bFGF. Just prior
to use, medium was equilibrated at 37◦C and 5% CO2 in
humidiﬁed air, 100μM 2-mercaptoethanol was added to the
KnockOut SR Xeno-Free Complete Medium. The iPSC col-
onies were picked for expansion and characterization from
days 21–25 of reprogramming.
2.3. Immunoﬂuorescence and Alkaline Phosphatase Staining.
Forimmunoﬂuorescencestaining,cellswereﬁxedin2%PFA
for 30 minutes at room temperature, blocked for 30 minutes
at room temperature in blocking buﬀer (5% normal goat
serum, 1% BSA, and 0.1% Triton X100 in D-PBS), incu-
bated with primary antibodies (diluted in blocking buﬀer)
overnight at 4◦C, washed 3X with D-PBS, incubated with
secondary antibodies (diluted in D-PBS) for 30 minutes
at room temperature, and washed 3X with D-PBS. ForStem Cells International 3
live staining, cells were washed 1X with DMEM/F-12 and
incubated with primary antibody at 1:100 dilution (in
DMEM/F-12) for 60min at 37◦C .C e l l sw e r ew a s h e d3 X
with DMEM/F12 and incubated with secondary antibody at
1:500 dilution (in DMEM/F-12) for 60 minutes at 37◦Ca n d
washed 3X with DMEM/F-12. Characterization was carried
out using the following antibodies: Mouse anti-Tra1-60
antibody (Cat. no. 41–1000), Mouse anti-Tra1-81 antibody
(Cat. no. 41–1100), Mouse anti-SSEA4 (Cat. no. 41–4000),
Alexa Fluor 488 goat anti-mouse IgG (H + L) antibody (Cat.
no. A11029), Alexa Fluor 594 goat anti-mouse IgG (H + L)
antibody (Cat. no. A11032), Alexa Fluor 488 goat anti-rabbit
IgG (H+L) antibody (Cat no. A11034), and Alexa Fluor 594
goat anti-rabbit IgG (H + L) antibody (Cat no. A11037). All
reagents are from Life Technologies. Clones were screened
forresidualvirususingrabbitanti-SeVantibody(MBLInter-
nationalCorporation,Woburn,MA;Cat.noPD029).Images
were captured using a Zeiss Axiovision microscope and
processed using AdobePhotoshop CS. Where applicable, on
day 25 of reprogramming, cells were stained using VECTOR
Red Alkaline Phosphatase Substrate Kit (Vector Labs Cat. no.
SK 5100) and positive colonies were counted.
2.4. RNA Isolation, qRT-PCR, and End Point PCR for Gene
Expression Analysis. Total RNA was extracted from cells
using TRIzol LS reagent (Cat. no. 10296-010) with DNaseI
(Cat.no.AM2222).RT-PCRreactionswerecarriedoutusing
20x Reverse Transcriptase enzyme mix and 2x RT Buﬀer
provided in the TaqMan Gene Expression Cells-to-CT Kit
(Cat. no. 4399002) with 1ug of total RNA per reaction. Gene
expression assays were performed according to the man-
ufacturer’s protocols. Primers for gene expression can be
found at http://www.invitrogen.com/site/us/en/home.html.
All reactions were performed in triplicates and normalized
to endogenous B-actin. End point PCR was performed with
10uLofcDNAin50uLofAccuPrimePfxSupermix(Cat.no.
12344040) with the following primers to detect for the pres-
ence of Sendai virus vector (SeV: Frw: GGATCACTAGGT-
GATATCGAGC, Rev: ACCAGACAAGAGTTTAAGAGATAT-
GTATC) as described in [19]. The expected size of the PCR
product is 181bp. All reagents are from Life Technologies.
PCRwasperformedwiththefollowingconditions:denatura-
tion 95◦C, 30sec, annealing: 55◦C, 30sec, elongation: 72◦C,
30sec, for 30–35 cycles. PCR products were analyzed on 2%
agarose gel electrophoresis.
2.5. MicroRNA Proﬁling. Total RNA was extracted from
cells using TRIzol LS reagent (Cat. no. 10296-010) with
DNASE 1 (Cat. no. AM2222). 500ng of total RNA was sub-
jected to cDNA synthesis using TaqMan MicroRNA Reverse
Transcription Kit (Cat. no. 4366597) and TaqMan Human
MicroRNA Array Card A (Cat. no. 4398965) to quantify
microRNAexpressionlevels,accordingtothemanufacturer’s
protocol. All reagents are from Life Technologies. Real-time
PCR was performed on an AB 7900HT Sequence Detection
System with cycling conditions of 95◦C for 10min followed
by 95◦C for 15sec and 60◦C for 60sec for a total of 40 cycles.
T h eC tv a l u e sf o ra l lm i R N A sw e r en o r m a l i z e dt om a m -
malian U6 snRNA levels by calculating their respective delta
Ct values. Relative changes in miRNA expression levels be-
tween samples were compared using the delta Ct values.
2.6. TaqMan Protein Assays and Reagents. All TaqMan Pro-
tein Assays and associated reagents kits were obtained from
Life Technologies. Cells were harvested, counted, and 50K
cells were incubated in 100uL of resuspension and 100uL of
lysis buﬀer. TaqMan Protein Assays were carried out with cell
lysate dilutions of 500 or 250 cells per reaction using Applied
Biosystems StepOnePlus real-time PCR system. In parallel,
the same cell inputs were also subjected to 18S genomic
ribosomal DNA assays to obtain endogenous control Cq,
described in [10].
2.7. In Vitro Diﬀerentiation of iPSCs. Undiﬀerentiated iPSCs
were harvested using collagenase to generate embryoid bod-
ies(EBs)andw er ecultur edfor4da ysinsuspensionindiﬀer-
entiation medium containing DMEM-F12 with GlutaMAX,
20% Knockout Serum Replacement, 1% nonessential amino
acid, and 55μM 2-mercaptoethanol (Life Technologies). On
day 5, EBs were seeded on Geltrex coated plates for an addi-
tional 17 days of diﬀerentiation in the same medium, then
the cells were used for immunocytochemistry. Induction to
neural lineages was performed as described in [23].
3. Results and Discussion
3.1. Generation of iPSCs with Sendai Virus Vector in Feeder-
Free or Xeno-Free Condition. Generation of human iPSCs
with Sendai virus vector encoding OCT3/4, KLF4, SOX2,
and cMYC was performed on feeder-free conditions with
StemPro hESC SFM and Geltrex coated plates, or xeno-free
conditions on KnockOut-DMEM/F-12 supplemented with
15% KnockOut-SR Xeno-Free CTS, and 1X KnockOut SR
GF Cocktail CTS on inactivated human feeders. Human ne-
onatal foreskin ﬁbroblast cells were plated onto a 6-well plate
two days before transduction, and approximately 5×105
cells were transduced with OCT3/4, KLF4, SOX2, and cMYC
Sendai virus vector at an MOI of 3. About 6-7 days after
transduction, cells were collected and transferred to Geltrex-
coated matrix plate (feeder-free condition) or onto inac-
tivated human feeders (xeno-free conditions) at the density
of 500,000 cells per 10cm dish for feeder-free condition and
200,000 cells per 10cm dish for xeno-free conditions. The
workﬂow is outlined in Figure 1, and viable colonies were
visible as early as day 10 after transduction, and these col-
onies could be readily picked by 21–25 days.
A majority of colonies generatedwith Sendai virus vector
have ES-like morphology, and very few transformed colonies
were observed. Clones from human ﬁbroblasts were stained
with pluripotent markers, SSEA4, Sox2, Nanog, and Tra1-
81 or Tra1-60 shown on Figure 2(A) (feeder-free condition)
and Figure 3(A) (xeno-free condition). Alkaline phosphatase
staining demonstrated eﬃciency on feeder-free condition to
be between 0.01 and 0.04%, and very few transformed or
non-iPSC colonies were detected, shown on Figure 2(C).
In addition, these cells were able to give rise to embryoid
bodies (EBs) that could diﬀerentiate to all the three lineages:
ectoderm, endoderm, and mesoderm (see Figure 2(B) for4 Stem Cells International
Reprogramming workﬂow
OCT MYC SOX KLF
Day 1
Day 2
Split cells to feeder-free or xeno-free condition
Feeder-free culture 
StemPro hESC SFM
Feeder-free culture 
StemPro hESC SFM
Colony formation 21–25 days post transduction
6-7 days after transduction
Remove virus and replace with growth medium
Figure 1: Reprogramming workﬂow on feeder-free and xeno-
free conditions. (1) Transduce cells with CytoTune Sendai virus
vector overnight. (2) Remove virus and replace with cell’s growth
medium. Cells are grown in cell’s growth medium for 6-7 days
after transduction. (3) Split cells onto Geltrex-coated plates or
inactivated human feeders. Culture transduced cells in feeder-free
conditions with StemPro hESC SFM medium and Geltrex-coated
plates or xeno-free medium consisting of KnockOut-DMEM/F-12,
15% KnockOut-SR Xeno-Free CTS, and 1X KnockOut SR Xeno-
FreeGrowthFactorCocktail.Coloniescanbepickedbetween17–25
days after transduction.
an example in feeder-free conditions and Figure 3(B) for
xeno-freeconditions).Wefurtherperformeddirectedinduc-
tion of clones from feeder-free condition to neural lineages
using N2B27 supplements as described in [23] and stained
cells with beta III tubulin Figure 2(D) (j) and nestin (k),
or by spontaneous diﬀerentiation that gave rise to beating
cardiomyocytes, Figure 2(D) (l). The diﬀerentiation proﬁle
was similar to that seen with cells reprogrammed with other
methods,andlittlevariationbetweendiﬀerentsubcloneswas
seen.
3.2.ExpressionofPluripotencyMarkersinDiﬀerentiPSCLines
by TaqMan Gene Expression and Protein Assays. We com-
paredgeneexpressionlevelsofOCT3/4,SOX2,NANOG,and
LIN28 of iPSC lines generated by Sendai virus vector or by
an episomal vector and found that expression proﬁle was
similar in all these lines as well as comparable to the WA09
embryonic stem cell line, shown on Figure 4(a).W ep r e v i -
ously demonstrated that TaqMan Protein Assays can be used
to characterize diﬀerent iPSC lines for the expression of
pluripotent protein markers and have reported variations
of protein levels among iPSC lines [10]. When iPSC lines
generated from Sendai virus vector were compared to an ep-
isomalgeneratediPSCline[24]ortheWA09hESCline,there
were subtle diﬀerences in the levels of protein expression
for OCT3/4, SOX2, NANOG, and LIN28 between diﬀerent
iPSC lines. Noticeably, SOX2 levels of the Sendai-generated
iPSC lines were lower than the episomal-generated iPSC
line and the WA09 hESC line (Figure 4(b)). It is likely that
the diﬀerence is due to the fact that the Sendai-generated
iPSC lines were at earlier passages (P5–P10) compared to the
episomaliPSC(>P20)ortheWA09hESCline.Thevariations
in the levels of the markers were within the range we have
observed iniPSlines generatedwithothermethods [10],and
in no case was the variation suﬃciently large that the cells
were not pluripotent as assessed by our in vitro assays. We
noticed that the diﬀerence becomes less noticeable when the
iPSC lines were at higher passages (data not shown). Recent
publication by Chung et al. reports that human-induced
pluripotent stem cells derived under feeder-free conditions
display similar levels of gene expression as in hESCs [25]. In
addition,thevariabilityamongiPSClinesisminimizedwhen
using a feeder-free culture system compared to on feeders
[25].
3.3. MicroRNA Proﬁling. We performed miRNA proﬁling
analysis with 384 unique miRNAs among three cell types,
BJ ﬁbroblasts, iPSCs generated with the Sendai virus vector,
and the WA09 human embryonic stem cell (hESC) line. Data
show poor correlation between BJ ﬁbroblast and the WA09
human embryonic stem cell (hESC) line Figure 5 (R2 =
0.3189). On the other hand, comparisons of the WA09 hu-
man embryonic stem cell (hESC) line and iPSC line gener-
ated from the Sendai virus vector were highly correlated
though subtle diﬀerences in miRNA expression (R2 =
0.9167), Figure 5, were observed. We also analyzed the “plu-
ripotent” miRNAs identiﬁed previously [26, 27]i nh u m a n
iPSCs and hESCs, speciﬁcally miR-302, miR-367–371, mi-
17–92, miR-299, and mi-Let 7 cluster, and found high
correlation between the WA09 human embryonic stem cell
(hESC) line and the iPSC line generated with Sendai virus
vector (R2 = 0.9662). These data demonstrate that the iPSC
line generated with Sendai virus vector is very similar to the
WA09 human embryonic stem cell (hESC) line as assessed by
miRNA proﬁling by qPCR.
3.4.DetectionofVirusFreeiPSCs. SinceSendaivirusvectoris
an RNA virus that only replicates constitutively in the cyto-
plasm of infected cells [13], it carries no risk of modifying
the host genome and it gradually lost as the cells proliferate.Stem Cells International 5
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Figure 2: (A) Characterization and diﬀerentiation of iPSC colonies generated on feeder-free conditions. Colonies were stained for
pluripotent markers: SSEA4 (b), SOX2 (c), Tra1-81 (e), NANOG (f), and phase ((a) and (d)). (B) These colonies were diﬀerentiated in vitro
into embryoid bodies (EBs) comprising of the three embryonic germ layers: endoderm marker α fetoprotein (AFP) (g), mesodermal marker
smooth muscle actin (SMA) (h), and ectoderm marker Beta 3-tubulin (Beta III) (i). (C) Colonies were stained with alkaline phosphatase
staining 25 days after transduction. (D) Colonies were also subjected to directed diﬀerentiation to neural stem cells, stained with Beta 3-
tubulin (Beta III) (j), Nestin (k), and random diﬀerentiation to beating cardiomyocytes (l).6 Stem Cells International
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Figure 3:(A)CharacterizationanddiﬀerentiationofiPSCcoloniesgeneratedonxeno-freeconditions.Colonieswerestainedforpluripotent
markers: NANOG (b), SSEA4 (c), SOX2 (e), Tra1-60 (f), and phase ((a) and (d)). (B) These colonies were diﬀerentiated in vitro into
embryoid bodies (EBs) comprising of the three embryonic germ layers: endoderm marker α fetoprotein (AFP) (g), mesodermal marker
smooth muscle actin (SMA) (h), and ectoderm marker Beta 3-tubulin (Beta III) (i).
We used two diﬀerent methods to detect loss of Sendai virus
vector in cells. Using RT-PCR with Sendai speciﬁc primers,
w ec a nd e t e c tt r a n s g e n e - R N A sa se a r l ya s2 4h o u r sa f t e r
transduction, Figure 6(a). The rate at which the transgenes
disappeared varies between each clone, and transgene-free
iPSC colonies were obtained by passage 10 using end point
PCR method, Figure 6(b).Thesecond method used to detect
the presence of Sendai virus vector is by immunochemistry
staining with anti-Sendai antibody. As early as passage 5, we
can detect some colonies staining negative for Sendai virus
vector, shown on Figure 7. Sendai virus vectors tend to dilute
out and disappear as the clones are being carried out to
further passages. By passage 10, residual Sendai transcripts
were completely eliminated in three out of four clones tested.
In addition, the Sendai backbone vector carries temperature-
sensitive mutations that enable complete removal of the
residual vector by shifting to nonpermissive temperature of
38-39◦C[ 22]. Thus, removal of Sendai virus vector is less
labor intensive compared to alternative methods that require
subsequent excision of transgenes from the host genome
[6, 28].
4. Conclusions
Sendai virus vector has been used as vectors for gene therapy
since it has no risk of being integrated into the host genome
and is nonpathogenic to humans. In addition, Sendai virus
vector has been shown to generate transgene-free human
iPSCs with high eﬃciency from ﬁbroblasts and CD34+ cord
blood cells [22]. In the present study, we demonstrated that
the Sendai virus vector can be used to generate transgene-
free human iPSCs in feeder-free and xeno-free conditions.
Comparing the feeder-based and feeder-free systems, we
noticed a decrease in reprogramming eﬃciency in feeder-
free conditions, independent of which media we used. Since
Sendai virus vector can reprogram with high eﬃciency, we
are able to obtain suﬃc i e n tn u m b e ro fc o l o n i e sf o rf u r t h e r
expansion in either condition. Another advantage of usingStem Cells International 7
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Figure 4: (a) TaqMan Gene Expression Assays of OCT4/POU5F1, SOX2, LIN28, and NANOG were compared among the WA09 hESC line,
an episomally derived iPSC line (Epi-line 1), and three Sendai-derived iPSC lines (Sendai 1, 3, and 6). Samples were normalized against the
endogenous reference B-actin. (b) TaqMan Protein Assays of OCT4/POU5F1, SOX2, LIN28, and NANOG are compared among the WA09
hESC line, an episomally derived iPSC line (Epi-line 1), and three Sendai-derived iPSC lines (Sendai 1, 3, and 6). Samples were normalized
against the endogenous reference 18S ribosomal genomic DNA and plotted relative fold change to the expression level of untransduced
human dermal ﬁbroblasts.
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Figure 5: ((a) and (b)) Scatter plots comparing microRNA expression proﬁles using the TaqMan Human MicroRNA Array of BJ ﬁbroblasts,
iPSCs generated with the Sendai virus vector (Sen-iPSC), and the WA09 human embryonic stem cell (hESC) line. ((c) and (d)) Scatter plots
comparing “pluripotent” microRNA expression proﬁles.
Sendai virus vector is the ease of use with single transduc-
tioncomparingtoothermethodsthatrequiremultipletrans-
fections [29]. Finally, iPSCs depleted of virus from the cyto-
plasm can be easily obtained without further manipulation.
Thus, the high eﬃciency and ease of use of the Sendai virus
vector is ideal for reprogramming with diﬀerent cell types on
feeder-based or feeder-free conditions.
GeneexpressionofpluripotentmarkersandmiRNApro-
ﬁling data show that iPSCs derived from Sendai virus vector
on feeder-free condition are similar to hESC line (the WA098 Stem Cells International
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Figure 6: (a) Detection of viral gene expression at 24 hours after transduction with Sendai virus vector by TaqMan Gene Expression Assays.
(b) Detection of virus-free iPSCs after 10 passages in culture by end-point PCR.
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Figure 7: Immunoﬂuorescence staining with anti-Sendai virus
vector antibodies to detect virus-free iPSCs. iPSC clones were
stained at passage 5.
embryonic stem cell line) and to another episomally derived
iPSC line. Our data is consistent with the recent publication
by Chung et al., which reports that feeder-free iPSCs have
similar transcriptomic proﬁles and diﬀerentiation capacity
to hESCs [25].Inaddition,increasingevidencedemonstrates
the importance of mircoRNAs (miRNAs) for human embry-
onicstemcellsself-renewal,pluripotency,anddiﬀerentiation
[27]. Previous publications reported a signature group of
miRNAs that is upregulated in both iPSCs and hESCs, such
as the miR-17–92 clusters, miR-290 clusters, miR-302, 367
cluster, miR-371/372/373, and let-7 family [26]. We further
compared these “pluripotent” miRNAs and found high
correlation between the human iPSCs generated by Sendai
virus vector and the WA09 human embryonic stem cell
(hESC) line. These data suggest that the nature of iPSCs gen-
eratedwithSendaivirusvectorissimilartothatofhESCline.
In summary, reports have shown that the use of integrat-
ing viruses to generate iPSCs is not ideal due to the potential
of tumorigenicity and the exposure of iPSCs in animal
containing products impedes downstream applications. It
is important to develop a system that can generate iPSCs
that are free of transgenes and in conditions that are free of
animal-derived products. Exposure of human cells to animal
origin products may increase immune rejection of grafted
cellsandmakethemunsuitableforthegenerationofclinical-
grade iPSCs [11]. Here we have demonstrated that iPSCs can
be generated in feeder-free or xeno-free conditions. Further,
the iPSCs generated here are free of transgenes and behave
similar to those generated on feeders or animal-derived
products. The generation of a footprint-free iPSCs under
these conditions should facilitate the safe clinical translation
of iPSC-based therapies.
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